DOI: 10.1128/AAC.02211-18
Article Information
PubMed
Published By
History
- Received October 19, 2018
- Returned for modification November 30, 2018
- Accepted January 3, 2019
- Published online February 26, 2019.
Copyright & Usage
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (January 07, 2019).
- You are viewing the most recent version of this article.
Author Information
- Thomas J. Dilwortha,
- Anthony M. Casapaob,
- Omar M. Ibrahimc,
- David M. Jacobsd,
- Dana R. Bowerse,
- Nicholas D. Beydaf and
- Renee-Claude Mercierg
- aAurora Health Care, Department of Pharmacy Services, Milwaukee, Wisconsin, USA
- bUniversity of Florida College of Pharmacy, Jacksonville, Florida, USA
- cIndependent Researcher, Gainesville, Florida, USA
- dUniversity at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA
- eWashington State University College of Pharmacy and Pharmaceutical Sciences, Yakima, Washington, USA
- fUniversity of Houston College of Pharmacy, Houston, Texas, USA
- gUniversity of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
- Address correspondence to Thomas J. Dilworth, thomas.dilworth{at}aurora.org.
Citation Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier R-C. 2019. Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus bacteremia: does β-lactam class matter? Antimicrob Agents Chemother 63:e02211-18. https://doi.org/10.1128/AAC.02211-18.
